Scholarlink

<p>Bipolar affective disorder (BAS) represents a&#xa0;significant challenge in psychiatric care owing to its severity and psychosocial impact. It is characterized by manic and depressive episodes and affects approximately 1–5% of the population. Despite extensive research, the pathophysiological mechanisms of BAS remain incompletely understood. Biological markers such as interleukins, tumor necrosis factor (TNF), and c-reactive protein (CRP), as well as structural brain changes such as those in white matter, have shown associations with disease progression and specific factors such as disease duration and the number of phases. Another promising area of research concerns neurofilaments (sNfL), which serve as markers for neuro-axonal damage. In one of our studies, we investigated whether sNfL correlates with the severity and course of BAS. Our results show that elevated sNfL levels are associated with longer disease duration and a&#xa0;higher number of manic episodes. These findings are consistent with previous studies and suggest that sNfL could be a&#xa0;potential biomarker for BAS. Overall, inflammatory and neurobiological markers, particularly in relation to neurodegenerative processes, could play an important role in the diagnosis and therapy of BAS in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neurofilamente als potenzielle Biomarker für die bipolare affektive Störung

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月27日

查看全文
  • Robert D. F. Queissner

摘要

Bipolar affective disorder (BAS) represents a significant challenge in psychiatric care owing to its severity and psychosocial impact. It is characterized by manic and depressive episodes and affects approximately 1–5% of the population. Despite extensive research, the pathophysiological mechanisms of BAS remain incompletely understood. Biological markers such as interleukins, tumor necrosis factor (TNF), and c-reactive protein (CRP), as well as structural brain changes such as those in white matter, have shown associations with disease progression and specific factors such as disease duration and the number of phases. Another promising area of research concerns neurofilaments (sNfL), which serve as markers for neuro-axonal damage. In one of our studies, we investigated whether sNfL correlates with the severity and course of BAS. Our results show that elevated sNfL levels are associated with longer disease duration and a higher number of manic episodes. These findings are consistent with previous studies and suggest that sNfL could be a potential biomarker for BAS. Overall, inflammatory and neurobiological markers, particularly in relation to neurodegenerative processes, could play an important role in the diagnosis and therapy of BAS in the future.